Workflow
外企:投资中国才能搭上发展快车,不跟上中国的步伐就会“掉队”
Zhong Guo Jing Ji Wang·2025-09-20 14:56

Core Insights - The Swiss company Medtronic has established a production base in Changzhou, China, focusing on the growing market for chronic disease management and self-injection devices [1][2] - The company has doubled its initial investment to €100 million, indicating strong confidence in the Chinese market [2] - The production facility is expected to start operations in June 2025, with an annual capacity of 100 million injection pens [2] Company Overview - Medtronic specializes in the development, production, and sales of injection pens and automatic injectors, serving major pharmaceutical companies globally [1] - The company has chosen Changzhou for its strategic advantages, including location, transportation, cost, and business environment [1][2] Market Dynamics - The demand for liquid formulations over traditional tablets is increasing, driven by better absorption rates, particularly for diabetes and obesity treatments [1] - The local industrial ecosystem in Changzhou supports Medtronic's operations, with nearby suppliers enhancing efficiency and reducing costs [3] Investment and Growth - The Changzhou project was approved in April 2023 and construction began in September 2023, with the main factory completed in just 14 months [2] - Medtronic's investment reflects a broader trend of foreign companies entering the Changzhou market, with foreign direct investment reaching $863 million in the first seven months of 2025, a year-on-year increase of 18.9% [5] Infrastructure and Logistics - The proximity to high-speed rail networks facilitates quick transportation to major cities like Shanghai and Nanjing, enhancing operational efficiency [6] - The local government is proactive in supporting foreign enterprises, contributing to a favorable business environment [2][5]